Hepalink Shifts To Drug Development With Resverlogix Deal
This article was originally published in PharmAsia News
Executive Summary
China's Shenzhen Hepalink Pharmaceutical, a publicly traded company that claims to be one of the largest makers of heparin in the world, has ambitions to build up its research and development activities for innovative drugs and is making substantial investments in overseas companies to achieve them.